Although several DNA-PKcs inhibitors have reached the pre-clinical evaluation stage, their use in patients have been limited by inadequate pharmacokinetics; as they are generally metabolically unstable, a high cellular concentration is unable to be achieved and therefore they are not clinically viable to potentiate other forms of cancer therapy. The gene discussed is PRKDC; the disease is cancer.